Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-pertussis whole-cell vaccine + inactivated poliovirus vaccine + Haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- National Institute for Public Health and the Environment
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria-tetanus-pertussis whole-cell vaccine + inactivated poliovirus vaccine + Haemophilus influenzae type b vaccine (DTPw-IPV-Hib) is a pentavalent pediatric combination vaccine. Developed by the Dutch National Institute for Public Health and the Environment (RIVM), it was historically the cornerstone of the Netherlands' national immunization program. The vaccine contains diphtheria and tetanus toxoids, killed whole-cell Bordetella pertussis bacteria, inactivated poliovirus (Salk strains), and the Haemophilus influenzae type b (Hib) capsular polysaccharide conjugated to a carrier protein. Unlike acellular pertussis vaccines (DTPa), the whole-cell component (DTPw) contains the entire killed bacterium, which has been shown in comparative studies to elicit a broader and more persistent cellular immune response. It is indicated for the active immunization of infants and children against diphtheria, tetanus, pertussis, poliomyelitis, and invasive Hib disease.
- Brand names
- DKTP-Hib
- Other names
- DTPw-IPV/HibDKTP-Hib vaccineDTP-IPV-Hib (whole-cell)
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria-tetanus-pertussis whole-cell vaccine + inactivated poliovirus vaccine + Haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-pertussis whole-cell vaccine + inactivated poliovirus vaccine + Haemophilus influenzae type b vaccine.